

ICMJE DISCLOSURE FORM

Date: December 01, 2022Your Name: Sri Harsha TellaManuscript Title: A Glimpse into the future of esophageal carcinoma in the United States: Predicting the future incidence until 2040 based on the current epidemiological dataManuscript number (if known): JGO-22-729-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None	
3	Royalties or licenses	☒ None	
4	Consulting fees	☒ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> X </u> None	
6	Payment for expert testimony	<u> X </u> None	
7	Support for attending meetings and/or travel	<u> X </u> None	
8	Patents planned, issued or pending	<u> X </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> X </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> X </u> None	
11	Stock or stock options	<u> X </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> X </u> None	
13	Other financial or non-financial interests	<u> X </u> None	

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

 X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: December 01, 2022Your Name: Kristin MaraManuscript Title: A Glimpse into the future of esophageal carcinoma in the United States: Predicting the future incidence until 2040 based on the current epidemiological dataManuscript number (if known): JGO-22-729-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None	
3	Royalties or licenses	☒ None	
4	Consulting fees	☒ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> X </u> None	
6	Payment for expert testimony	<u> X </u> None	
7	Support for attending meetings and/or travel	<u> X </u> None	
8	Patents planned, issued or pending	<u> X </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> X </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> X </u> None	
11	Stock or stock options	<u> X </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> X </u> None	
13	Other financial or non-financial interests	<u> X </u> None	

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

 X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: December 01, 2022Your Name: Sakti ChakrabartiManuscript Title: A Glimpse into the future of esophageal carcinoma in the United States: Predicting the future incidence until 2040 based on the current epidemiological dataManuscript number (if known): JGO-22-729-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None	
3	Royalties or licenses	☒ None	
4	Consulting fees	☒ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ X ☐ Yes	Honoraria from Haliodx, QED Therapeutics, Natera, and speakers' bureau for Natera. None of this is related to the work presented.
6	Payment for expert testimony	☒ X ☐ None	
7	Support for attending meetings and/or travel	☒ X ☐ None	
8	Patents planned, issued or pending	☒ X ☐ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ X ☐ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ X ☐ None	
11	Stock or stock options	☒ X ☐ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ X ☐ None	
13	Other financial or non-financial interests	☒ X ☐ None	

Please summarize the above conflict of interest in the following box:

Sakti Chakrabarti has honoraria from Haliodx, QED Therapeutics, Natera, and speakers' bureau for Natera, not related to the work presented

Please place an "X" next to the following statement to indicate your agreement:

☒ X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: December 01, 2022Your Name: Zhaohui JinManuscript Title: A Glimpse into the future of esophageal carcinoma in the United States: Predicting the future incidence until 2040 based on the current epidemiological dataManuscript number (if known): JGO-22-729-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>__X__</u> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>__X__</u> None	
3	Royalties or licenses	<u>__X__</u> None	
4	Consulting fees	<u>__X__</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ X ☐ None	
6	Payment for expert testimony	☒ X ☐ None	
7	Support for attending meetings and/or travel	☒ X ☐ None	
8	Patents planned, issued or pending	☒ X ☐ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☐ Yes	Novartis (Inst), QED Therapeutics (Inst), Lilly (Inst), GlaxoSmithKline (Inst), and Daiichi Sankyo/Astra Zeneca (Inst). All to the institution- not related to the work discussed here
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ X ☐ None	
11	Stock or stock options	☒ X ☐ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ X ☐ None	
13	Other financial or non-financial interests	☒ X ☐ None	

Please summarize the above conflict of interest in the following box:

Zhaohui Jin has consulting or advisory Role for Novartis (Inst), QED Therapeutics (Inst), Lilly (Inst), GlaxoSmithKline (Inst), and Daiichi Sankyo/Astra Zeneca (Inst).

Please place an "X" next to the following statement to indicate your agreement:

☒ X ☐ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: December 01, 2022Your Name: Amit MahipalManuscript Title: A Glimpse into the future of esophageal carcinoma in the United States: Predicting the future incidence until 2040 based on the current epidemiological dataManuscript number (if known): JGO-22-729-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None	
3	Royalties or licenses	☒ None	
4	Consulting fees	☒ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ X ☐ None	
6	Payment for expert testimony	☒ X ☐ None	
7	Support for attending meetings and/or travel	☐ X ☐ None	
8	Patents planned, issued or pending	☒ X ☐ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☐ Yes	Taiho oncology, Astrazeneca and QED Therapeutics
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ X ☐ None	
11	Stock or stock options	☐ X ☐ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ X ☐ None	
13	Other financial or non-financial interests	☒ X ☐ None	

Please summarize the above conflict of interest in the following box:

Amit Mahipal serves in the advisory Board for, Taiho oncology, Astrazeneca and QED Therapeutics

Please place an "X" next to the following statement to indicate your agreement:

☒ X I certify that I have answered every question and have not altered the wording of any of the questions on this form.